Gene clues may predict breast cancer drug success
NCT ID NCT02329639
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examined whether specific gene variations influence how well metastatic breast cancer patients respond to chemotherapy with or without the drug bevacizumab. Researchers enrolled 307 women from Italy to compare outcomes and analyze genetic interactions. The goal was to understand which patients might benefit most from adding bevacizumab to standard chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda USL 5 of Pisa
Pontedera, Pisa, 56025, Italy
-
Department of Clinical and Experimental Medicine, University of Pisa
Pisa, I Am Not in the U.S. Or Canada, 56125, Italy